59
Participants
Start Date
March 22, 2017
Primary Completion Date
August 13, 2018
Study Completion Date
November 7, 2018
SOF/VEL
400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
Auckland City Hospital, Grafton
Royal Adelaide Hospital, Adelaide
Hospital Universitario Puerta de Hierro - Majadahonda, Majadahonda
Hospital Universitario Fundación Alcorcón, Alcorcón
Hospital Universitario Virgen del Rocío, Seville
The Chaim Sheba Medical Centre, Ramat Gan
Tel Aviv Sourasky Medical Center, Tel Aviv
Shaare Zedek Medical Center, Jerusalem
Kaye Edmonton Clinic, Edmonton
William Osler Health System- Brampton Civic Hospital, Brampton
Gordon and Leslie Diamond Health Care Center, Vancouver General Hospital, UBC Division of Gastroenterology, Vancouver
Hamilton Health Sciences - McMaster University Medical Centre Site, Hamilton
Ottawa Hospital Research Institute, Ottawa
Centre de Recherche du Centre Hospitalier de l'Universite de Montreal (CRCHUM), Montreal
Hospital Universitari Vall d'Hebron, Barcelona
Gartnavel General Hospital, Glasgow
Barts Health NHS Trust, London
King's College Hospital, London
Chelsea and Westminster Hospital, London
Imperial College Healthcare NHS Trust, London
Nottingham University Hospitals NHS Trust, Nottingham
Derriford Hospital, Plymouth
Lead Sponsor
Gilead Sciences
INDUSTRY